{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:16:59Z","timestamp":1792783019286,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The National Natural Science Foundation of China","award":["81703493"],"award-info":[{"award-number":["81703493"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The Natural Science Foundation of Jiangsu Province","award":["BK20170258"],"award-info":[{"award-number":["BK20170258"]}]},{"name":"The Natural Science Foundation of Jiangsu Province","award":["BK20221222"],"award-info":[{"award-number":["BK20221222"]}]},{"name":"The China Postdoctoral Science Foundation\u2011funded projects","award":["No. 2019M661943"],"award-info":[{"award-number":["No. 2019M661943"]}],"id":[{"id":"https:\/\/ror.org\/0426zh255","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The Foundation of Xuzhou Science and Technology Department","award":["No. KC21154"],"award-info":[{"award-number":["No. KC21154"]}]},{"name":"The Paired Assistance Scientific Research Project by The Affiliated Hospital of Xuzhou Medical University","award":["SHJDBF2024218"],"award-info":[{"award-number":["SHJDBF2024218"]}],"id":[{"id":"https:\/\/ror.org\/02kstas42","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10557-026-07871-w","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T06:12:16Z","timestamp":1776751936000},"page":"1809-1823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Possible clinical drug interactions between ticagrelor and concomitant medications: for adverse drug event monitoring in real-world"],"prefix":"10.1007","volume":"40","author":[{"given":"Tianya","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"7871_CR1","doi-asserted-by":"publisher","unstructured":"Nappi F. P2Y12 Receptor Inhibitor for Antiaggregant Therapies: From Molecular Pathway to Clinical Application. Int J Mol Sci. 2024;25(14). https:\/\/doi.org\/10.3390\/ijms25147575.","DOI":"10.3390\/ijms25147575"},{"issue":"10","key":"7871_CR2","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/phar.1477","volume":"34","author":"PP Dobesh","year":"2014","unstructured":"Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2014;34(10):1077\u201390. https:\/\/doi.org\/10.1002\/phar.1477.","journal-title":"Pharmacotherapy"},{"issue":"23","key":"7871_CR3","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1161\/CIRCULATIONAHA.111.082727","volume":"125","author":"SK James","year":"2012","unstructured":"James SK, Storey RF, Khurmi NS, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation. 2012;125(23):2914\u201321. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.082727.","journal-title":"Circulation"},{"issue":"1","key":"7871_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/neuros\/nyy002","volume":"84","author":"AP Narata","year":"2019","unstructured":"Narata AP, Amelot A, Bibi R, et al. Dual Antiplatelet Therapy Combining Aspirin and Ticagrelor for Intracranial Stenting Procedures: A Retrospective Single Center Study of 154 Consecutive Patients With Unruptured Aneurysms. Neurosurgery. 2019;84(1):77\u201383. https:\/\/doi.org\/10.1093\/neuros\/nyy002.","journal-title":"Neurosurgery"},{"issue":"4","key":"7871_CR5","doi-asserted-by":"publisher","first-page":"e013263","DOI":"10.1161\/CIRCINTERVENTIONS.123.013263","volume":"17","author":"A Spirito","year":"2024","unstructured":"Spirito A, Krishnan SL, Capodanno D, Angiolillo DJ, Mehran R. Antiplatelet De-Escalation Strategies in Patients Undergoing Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2024;17(4):e013263. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.123.013263.","journal-title":"Circ Cardiovasc Interv"},{"issue":"2","key":"7871_CR6","doi-asserted-by":"publisher","first-page":"e70258","DOI":"10.1111\/cns.70258","volume":"31","author":"X Huang","year":"2025","unstructured":"Huang X, Song J, Zhang X, et al. Understanding Drug Interactions in Antiplatelet Therapy for Atherosclerotic Vascular Disease: A Systematic Review. CNS Neurosci Ther. 2025;31(2):e70258. https:\/\/doi.org\/10.1111\/cns.70258.","journal-title":"CNS Neurosci Ther"},{"issue":"10","key":"7871_CR7","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s11095-021-03105-w","volume":"38","author":"S Liu","year":"2021","unstructured":"Liu S, Sodhi JK, Benet LZ. Analyzing Potential Intestinal Transporter Drug-Drug Interactions: Reevaluating Ticagrelor Interaction Studies. Pharm Res. 2021;38(10):1639\u201344. https:\/\/doi.org\/10.1007\/s11095-021-03105-w.","journal-title":"Pharm Res"},{"key":"7871_CR8","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.15420\/ecr.2025.12","volume":"20","author":"E Bigagli","year":"2025","unstructured":"Bigagli E, Angelini J, Mugelli A, Rocca B. Oral P2Y(12) Inhibitors: Victims or Perpetrators? A Focused Review on Pharmacokinetic, Clinically Relevant Drug Interactions. Eur Cardiol. 2025;20:e17. https:\/\/doi.org\/10.15420\/ecr.2025.12.","journal-title":"Eur Cardiol"},{"issue":"6","key":"7871_CR9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s10557-024-07624-7","volume":"38","author":"B Rocca","year":"2024","unstructured":"Rocca B, Bigagli E, Cerbai E. Ticagrelor and Statins: Dangerous Liaisons? Cardiovasc Drugs Ther. 2024;38(6):1103\u20139. https:\/\/doi.org\/10.1007\/s10557-024-07624-7.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"7871_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.11909\/j.issn.1671-5411.2016.03.007","volume":"13","author":"Y Yan","year":"2016","unstructured":"Yan Y, Wang X, Fan JY, et al. Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome. J Geriatr Cardiol. 2016;13(3):209\u201317. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2016.03.007.","journal-title":"J Geriatr Cardiol"},{"key":"7871_CR11","doi-asserted-by":"publisher","first-page":"970066","DOI":"10.3389\/fphar.2022.970066","volume":"13","author":"S Tang","year":"2022","unstructured":"Tang S, Wu Z, Xu L, Wen Q, Zhang X. Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS. Front Pharmacol. 2022;13:970066. https:\/\/doi.org\/10.3389\/fphar.2022.970066.","journal-title":"Front Pharmacol"},{"issue":"2","key":"7871_CR12","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1097\/JS9.0000000000002194","volume":"111","author":"H Liu","year":"2025","unstructured":"Liu H, Yang Q, Li Z, Yan S, Ming S. Systematic analysis of sugammadex-related adverse drug reaction signals using FAERS database. Int J Surg. 2025;111(2):1988\u201394. https:\/\/doi.org\/10.1097\/JS9.0000000000002194.","journal-title":"Int J Surg"},{"issue":"1","key":"7871_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.12997\/jla.2024.13.1.61","volume":"13","author":"R Patel","year":"2024","unstructured":"Patel R, Sharma JB, Rajput S. Statins Ticagrelor and Rhabdomyolysis: A Coincidence or a Drug Interaction? J Lipid Atheroscler. 2024;13(1):61\u20138. https:\/\/doi.org\/10.12997\/jla.2024.13.1.61.","journal-title":"J Lipid Atheroscler"},{"issue":"3","key":"7871_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s11096-022-01514-4","volume":"45","author":"L Wei","year":"2023","unstructured":"Wei L, Tian Y, Chen X, et al. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database. Int J Clin Pharm. 2023;45(3):622\u20139. https:\/\/doi.org\/10.1007\/s11096-022-01514-4.","journal-title":"Int J Clin Pharm"},{"issue":"11","key":"7871_CR15","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1080\/14740338.2024.2376693","volume":"23","author":"M Li","year":"2024","unstructured":"Li M, Xiao J, Yu T, et al. Analysis of hemorrhagic drug-drug interactions between P-gp inhibitors and direct oral anticoagulants from the FDA Adverse Event Reporting System. Expert Opin Drug Saf. 2024;23(11):1453\u201361. https:\/\/doi.org\/10.1080\/14740338.2024.2376693.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"7871_CR16","doi-asserted-by":"publisher","first-page":"e0300268","DOI":"10.1371\/journal.pone.0300268","volume":"19","author":"D Jung","year":"2024","unstructured":"Jung D, Jung I. A simulation-based comparison of drug-drug interaction signal detection methods. PLoS ONE. 2024;19(4):e0300268. https:\/\/doi.org\/10.1371\/journal.pone.0300268.","journal-title":"PLoS ONE"},{"key":"7871_CR17","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3389\/fphar.2019.01319","volume":"10","author":"Y Noguchi","year":"2019","unstructured":"Noguchi Y, Tachi T, Teramachi H. Review of Statistical Methodologies for Detecting Drug-Drug Interactions Using Spontaneous Reporting Systems. Front Pharmacol. 2019;10:1319. https:\/\/doi.org\/10.3389\/fphar.2019.01319.","journal-title":"Front Pharmacol"},{"issue":"16","key":"7871_CR18","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/sim.3247","volume":"27","author":"GN Noren","year":"2008","unstructured":"Noren GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug-drug interaction surveillance. Stat Med. 2008;27(16):3057\u201370. https:\/\/doi.org\/10.1002\/sim.3247.","journal-title":"Stat Med"},{"issue":"7","key":"7871_CR19","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/sim.8457","volume":"39","author":"X Wang","year":"2020","unstructured":"Wang X, Li L, Wang L, Feng W, Zhang P. Propensity score-adjusted three-component mixture model for drug-drug interaction data mining in FDA Adverse Event Reporting System. Stat Med. 2020;39(7):996\u20131010. https:\/\/doi.org\/10.1002\/sim.8457.","journal-title":"Stat Med"},{"key":"7871_CR20","doi-asserted-by":"publisher","unstructured":"Noguchi Y, Aoyama K, Kubo S, Tachi T, Teramachi H. Improved Detection Criteria for Detecting Drug-Drug Interaction Signals Using the Proportional Reporting Ratio. Pharmaceuticals (Basel). 2020;14(1). https:\/\/doi.org\/10.3390\/ph14010004.","DOI":"10.3390\/ph14010004"},{"issue":"8","key":"7871_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1055\/s-0032-1328890","volume":"38","author":"TJ Moore","year":"2012","unstructured":"Moore TJ, Bennett CL. Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012;38(8):905\u20137. https:\/\/doi.org\/10.1055\/s-0032-1328890.","journal-title":"Semin Thromb Hemost"},{"key":"7871_CR22","doi-asserted-by":"publisher","unstructured":"Noguchi Y, Yoshizawa S, Aoyama K, et al. Verification of the Upward Variation in the Reporting Odds Ratio Scores to Detect the Signals of Drug-Drug Interactions. Pharmaceutics. 2021;13(10). https:\/\/doi.org\/10.3390\/pharmaceutics13101531.","DOI":"10.3390\/pharmaceutics13101531"},{"key":"7871_CR23","doi-asserted-by":"publisher","first-page":"1251961","DOI":"10.3389\/fphar.2024.1251961","volume":"15","author":"Y Pan","year":"2024","unstructured":"Pan Y, Wang Y, Zheng Y, Chen J, Li J. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor. Front Pharmacol. 2024;15:1251961. https:\/\/doi.org\/10.3389\/fphar.2024.1251961.","journal-title":"Front Pharmacol"},{"key":"7871_CR24","doi-asserted-by":"publisher","unstructured":"Noguchi Y, Tachi T, Teramachi H. Subset Analysis for Screening Drug-Drug Interaction Signal Using Pharmacovigilance Database. Pharmaceutics. 2020;12(8). https:\/\/doi.org\/10.3390\/pharmaceutics12080762.","DOI":"10.3390\/pharmaceutics12080762"},{"key":"7871_CR25","doi-asserted-by":"publisher","first-page":"1292163","DOI":"10.3389\/fphar.2024.1292163","volume":"15","author":"BN Huo","year":"2024","unstructured":"Huo BN, Shu L, Xiao JW, et al. Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events. Front Pharmacol. 2024;15:1292163. https:\/\/doi.org\/10.3389\/fphar.2024.1292163.","journal-title":"Front Pharmacol"},{"issue":"6","key":"7871_CR26","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s10557-023-07459-8","volume":"38","author":"V Roule","year":"2024","unstructured":"Roule V, Alexandre J, Lemaitre A, et al. Rhabdomyolysis with Co-Administration of Statins and Antiplatelet Therapies-Analysis of the WHO Pharmacovigilance Database. Cardiovasc Drugs Ther. 2024;38(6):1191\u20139. https:\/\/doi.org\/10.1007\/s10557-023-07459-8.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7871_CR27","doi-asserted-by":"publisher","first-page":"3801819","DOI":"10.1155\/2017\/3801819","volume":"2017","author":"I Banakh","year":"2017","unstructured":"Banakh I, Haji K, Kung R, Gupta S, Tiruvoipati R. Severe Rhabdomyolysis due to Presumed Drug Interactions between Atorvastatin with Amlodipine and Ticagrelor. Case Rep Crit Care. 2017;2017:3801819. https:\/\/doi.org\/10.1155\/2017\/3801819.","journal-title":"Case Rep Crit Care"},{"key":"7871_CR28","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2147\/TCRM.S515732","volume":"21","author":"AS Alshammari","year":"2025","unstructured":"Alshammari AS, Shalwala AA, Alnuhait MA, et al. Muscular and Renal Safety of Ticagrelor with High-Intensity Statins: Retrospective Cohort Findings. Ther Clin Risk Manag. 2025;21:861\u20137. https:\/\/doi.org\/10.2147\/TCRM.S515732.","journal-title":"Ther Clin Risk Manag"},{"key":"7871_CR29","doi-asserted-by":"publisher","unstructured":"Na YG, Byeon JJ, Huh HW, et al. Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats. Pharmaceutics. 2019;11(7). https:\/\/doi.org\/10.3390\/pharmaceutics11070354.","DOI":"10.3390\/pharmaceutics11070354"},{"issue":"5","key":"7871_CR30","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/pds.3199","volume":"21","author":"CG Rowan","year":"2012","unstructured":"Rowan CG, Brunelli SM, Munson J, et al. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf. 2012;21(5):494\u2013506. https:\/\/doi.org\/10.1002\/pds.3199.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"7871_CR31","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1111\/bcp.15684","volume":"89","author":"M Lehtisalo","year":"2023","unstructured":"Lehtisalo M, Kiander W, Filppula AM, et al. Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein-mediated drug interaction? Br J Clin Pharmacol. 2023;89(7):2309\u201315. https:\/\/doi.org\/10.1111\/bcp.15684.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"7871_CR32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00228-012-1369-4","volume":"69","author":"R Teng","year":"2013","unstructured":"Teng R, Mitchell PD, Butler KA. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol. 2013;69(3):477\u201387. https:\/\/doi.org\/10.1007\/s00228-012-1369-4.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"7871_CR33","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.111.032912","volume":"125","author":"SG Goodman","year":"2012","unstructured":"Goodman SG, Clare R, Pieper KS, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012;125(8):978\u201386. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.032912.","journal-title":"Circulation"},{"issue":"5","key":"7871_CR34","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.hjc.2019.06.001","volume":"61","author":"F Zhang","year":"2020","unstructured":"Zhang F, Su S, Hou Y, et al. Effects (MACE and bleeding events) of ticagrelor combined with omeprazole on patients with acute myocardial infarction undergoing primary PCI. Hellenic J Cardiol. 2020;61(5):306\u201310. https:\/\/doi.org\/10.1016\/j.hjc.2019.06.001.","journal-title":"Hellenic J Cardiol"},{"issue":"11","key":"7871_CR35","doi-asserted-by":"publisher","first-page":"e020413","DOI":"10.1161\/JAHA.120.020413","volume":"10","author":"J Qu","year":"2021","unstructured":"Qu J, Zhang H, Rao C, et al. Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery. J Am Heart Assoc. 2021;10(11):e020413. https:\/\/doi.org\/10.1161\/JAHA.120.020413.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"7871_CR36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/ehjcvp\/pvae080","volume":"11","author":"U Baber","year":"2025","unstructured":"Baber U, Cao D, Collier T, et al. Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial. Eur Heart J Cardiovasc Pharmacother. 2025;11(1):66\u201374. https:\/\/doi.org\/10.1093\/ehjcvp\/pvae080.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"7871_CR37","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1182\/hematology.2020000151","volume":"2020","author":"GD Barnes","year":"2020","unstructured":"Barnes GD. Combining antiplatelet and anticoagulant therapy in cardiovascular disease. Hematol Am Soc Hematol Educ Program. 2020;2020(1):642\u20138. https:\/\/doi.org\/10.1182\/hematology.2020000151.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"7871_CR38","doi-asserted-by":"publisher","first-page":"117954682513612","DOI":"10.1177\/11795468251361209","volume":"19","author":"O Almur","year":"2025","unstructured":"Almur O, Emran B, Milhem F, et al. Controversies in Antithrombotic Therapy for Patients With Coronary Artery Disease and Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Literature Review. Clin Med Insights Cardiol. 2025;19:11795468251361209. https:\/\/doi.org\/10.1177\/11795468251361209.","journal-title":"Clin Med Insights Cardiol"},{"issue":"4","key":"7871_CR39","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1755-5922.2009.00096.x","volume":"27","author":"S Husted","year":"2009","unstructured":"Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27(4):259\u201374. https:\/\/doi.org\/10.1111\/j.1755-5922.2009.00096.x.","journal-title":"Cardiovasc Ther"},{"key":"7871_CR40","doi-asserted-by":"publisher","unstructured":"Gray E, Hogwood J, Mulloy B. The anticoagulant and antithrombotic mechanisms of heparin. Handb Exp Pharmacol. 2012;20743\u201361. https:\/\/doi.org\/10.1007\/978-3-642-23056-1_3.","DOI":"10.1007\/978-3-642-23056-1_3"},{"key":"7871_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.thromres.2018.09.046","volume":"171","author":"D Venetsanos","year":"2018","unstructured":"Venetsanos D, Lindahl TL, Lawesson SS, et al. Pretreatment with ticagrelor may offset additional inhibition of platelet and coagulation activation with bivalirudin compared to heparin during primary percutaneous coronary intervention. Thromb Res. 2018;171:38\u201344. https:\/\/doi.org\/10.1016\/j.thromres.2018.09.046.","journal-title":"Thromb Res"},{"issue":"1","key":"7871_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/ehjacc\/zuad107","volume":"13","author":"RA Byrne","year":"2024","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J Acute Cardiovasc Care. 2024;13(1):55\u2013161. https:\/\/doi.org\/10.1093\/ehjacc\/zuad107.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"14","key":"7871_CR43","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","volume":"381","author":"PG Steg","year":"2019","unstructured":"Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019;381(14):1309\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1908077.","journal-title":"N Engl J Med"},{"issue":"3","key":"7871_CR44","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/eurheartj\/ehv547","volume":"37","author":"J Kubica","year":"2016","unstructured":"Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016;37(3):245\u201352. https:\/\/doi.org\/10.1093\/eurheartj\/ehv547.","journal-title":"Eur Heart J"},{"issue":"16","key":"7871_CR45","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1503\/cmaj.100912","volume":"183","author":"C Labos","year":"2011","unstructured":"Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ. 2011;183(16):1835\u201343. https:\/\/doi.org\/10.1503\/cmaj.100912.","journal-title":"CMAJ"},{"issue":"1","key":"7871_CR46","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/07853890.2021.2017474","volume":"54","author":"S Nochaiwong","year":"2022","unstructured":"Nochaiwong S, Ruengorn C, Awiphan R, et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med. 2022;54(1):80\u201397. https:\/\/doi.org\/10.1080\/07853890.2021.2017474.","journal-title":"Ann Med"},{"issue":"1","key":"7871_CR47","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1365-2125.2005.02507.x","volume":"61","author":"SW Grimm","year":"2006","unstructured":"Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006;61(1):58\u201369. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02507.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"7871_CR48","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/s0301-0082(98)00071-9","volume":"57","author":"C Tassorelli","year":"1999","unstructured":"Tassorelli C, Joseph SA, Buzzi MG, Nappi G. The effects on the central nervous system of nitroglycerin\u2013putative mechanisms and mediators. Prog Neurobiol. 1999;57(6):607\u201324. https:\/\/doi.org\/10.1016\/s0301-0082(98)00071-9.","journal-title":"Prog Neurobiol"},{"issue":"1\u20133","key":"7871_CR49","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejphar.2013.09.032","volume":"721","author":"A Saxena","year":"2013","unstructured":"Saxena A, Balaramnavar VM, Hohlfeld T, Saxena AK. Drug\/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets. Eur J Pharmacol. 2013;721(1\u20133):215\u201324. https:\/\/doi.org\/10.1016\/j.ejphar.2013.09.032.","journal-title":"Eur J Pharmacol"},{"key":"7871_CR50","doi-asserted-by":"publisher","first-page":"e65872","DOI":"10.2196\/65872","volume":"27","author":"H Ji","year":"2025","unstructured":"Ji H, Gong M, Gong L, et al. Detection of Clinically Significant Drug-Drug Interactions in Fatal Torsades de Pointes: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System. J Med Internet Res. 2025;27:e65872. https:\/\/doi.org\/10.2196\/65872.","journal-title":"J Med Internet Res"},{"issue":"6","key":"7871_CR51","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/j.1476-5381.2010.00750.x","volume":"160","author":"TK Ma","year":"2010","unstructured":"Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol. 2010;160(6):1273\u201392. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00750.x.","journal-title":"Br J Pharmacol"},{"key":"7871_CR52","doi-asserted-by":"publisher","unstructured":"Haliga RE, Cojocaru E, Sirbu O, et al. Immunomodulatory Effects of RAAS Inhibitors: Beyond Hypertension and Heart Failure. Biomedicines. 2025;13(7). https:\/\/doi.org\/10.3390\/biomedicines13071779.","DOI":"10.3390\/biomedicines13071779"},{"issue":"11","key":"7871_CR53","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/clc.22063","volume":"35","author":"JJ DiNicolantonio","year":"2012","unstructured":"DiNicolantonio JJ, Serebruany VL. Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction? Clin Cardiol. 2012;35(11):647\u20138. https:\/\/doi.org\/10.1002\/clc.22063.","journal-title":"Clin Cardiol"},{"issue":"3","key":"7871_CR54","doi-asserted-by":"publisher","first-page":"e5768","DOI":"10.1002\/pds.5768","volume":"33","author":"XF Jiao","year":"2024","unstructured":"Jiao XF, Pu L, Lan S, et al. Adverse drug reaction signal detection methods in spontaneous reporting system: A systematic review. Pharmacoepidemiol Drug Saf. 2024;33(3):e5768. https:\/\/doi.org\/10.1002\/pds.5768.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7871_CR55","doi-asserted-by":"publisher","first-page":"104639","DOI":"10.1016\/j.jbi.2024.104639","volume":"153","author":"E Jeong","year":"2024","unstructured":"Jeong E, Su Y, Li L, Chen Y. Discovering clinical drug-drug interactions with known pharmacokinetics mechanisms using spontaneous reporting systems and electronic health records. J Biomed Inf. 2024;153:104639. https:\/\/doi.org\/10.1016\/j.jbi.2024.104639.","journal-title":"J Biomed Inf"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07871-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07871-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07871-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:29:32Z","timestamp":1789522172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07871-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["7871"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07871-w","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used AI in order to improve language of the article. After using AI the authors reviewed and edited the contents as needed and took full responsibility for the contents of the publication.","order":2,"name":"Ethics","label":"<b>Declarations of Generative AI and AI-Assisted Technologies in the Writing process<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}]}}